Acumen Pharmaceuticals Q2 net loss widens, misses analyst estimates
Acumen Pharmaceuticals Q2 net loss widens, misses analyst estimates
Overview
US Alzheimer's therapeutics developer's Q2 net loss missed analyst expectations
Q2 loss from operations also missed analyst estimates
R&D expenses fell yr/yr due to lower manufacturing and CRO costs for ALTITUDE-AD trial
Outlook
Company expects topline results from ALTITUDE-AD Phase 2 study in late 2026
Acumen targets IND filing for EBD program lead candidate in mid-2027
Company expects cash to support operations into early 2027
Result Drivers
R&D EXPENSES - Lower manufacturing and CRO costs for the ALTITUDE-AD clinical trial led to a decrease in R&D expenses
PIPELINE PROGRESS - Nomination of two Enhanced Brain Delivery program candidates and IND-enabling activities advanced pipeline development
Company press release: ID:nGNX6lcGDS
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Loss | Miss | $32.72 mln | $23.28 mln (5 Analysts) |
Q2 Income From Operations | Miss | -$32.56 mln | -$24.58 mln (5 Analysts) |
Q2 Loss Per Basic Share |
| $0.45 |
|
Q2 Operating Expenses |
| $32.56 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Acumen Pharmaceuticals Inc is $8.00, about 223.9% above its August 11 closing price of $2.47
Reuters Recommended Reads
Aug 11 - Coya Therapeutics Q2 net loss widens as R&D costs rise
Aug 10 - CervoMed Q2 net loss lower than estimates as costs drop
Aug 11 - Gain Therapeutics Q2 net loss per share narrows as R&D expenses fall
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)